Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance

Donnele Daley, Vishnu R. Mani, Navyatha Mohan, Neha Akkad, Atsuo Ochi, Daniel W. Heindel, Ki Buom Lee, Constantinos P. Zambirinis, Gautam SD Balasubramania Pandian, Shivraj Savadkar, Alejandro Torres-Hernandez, Shruti Nayak, Ding Wang, Mautin Hundeyin, Brian Diskin, Berk Aykut, Gregor Werba, Rocky M. Barilla, Robert Rodriguez, Steven ChangLawrence Gardner, Lara Mahal, Beatrix Ueberheide, George Miller

Research output: Contribution to journalArticle

Abstract

The progression of pancreatic oncogenesis requires immune-suppressive inflammation in cooperation with oncogenic mutations. However, the drivers of intratumoral immune tolerance are uncertain. Dectin 1 is an innate immune receptor crucial for anti-fungal immunity, but its role in sterile inflammation and oncogenesis has not been well defined. Furthermore, non-pathogen-derived ligands for dectin 1 have not been characterized. We found that dectin 1 is highly expressed on macrophages in pancreatic ductal adenocarcinoma (PDA). Dectin 1 ligation accelerated the progression of PDA in mice, whereas deletion of Clec7a—the gene encoding dectin 1—or blockade of dectin 1 downstream signaling was protective. We found that dectin 1 can ligate the lectin galectin 9 in mouse and human PDA, which results in tolerogenic macrophage programming and adaptive immune suppression. Upon disruption of the dectin 1–galectin 9 axis, CD4+ and CD8+ T cells, which are dispensable for PDA progression in hosts with an intact signaling axis, become reprogrammed into indispensable mediators of anti-tumor immunity. These data suggest that targeting dectin 1 signaling is an attractive strategy for developing an immunotherapy for PDA.

Original languageEnglish (US)
JournalNature Medicine
DOIs
StateAccepted/In press - Apr 10 2017

Fingerprint

Galectins
Immune Tolerance
Macrophage Activation
Macrophages
Chemical activation
Adenocarcinoma
Immunity
Carcinogenesis
Inflammation
Gene encoding
T-cells
Gene Deletion
dectin 1
Pancreatic Carcinoma
Lectins
Immunotherapy
Ligation
Tumors
Ligands
T-Lymphocytes

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Daley, D., Mani, V. R., Mohan, N., Akkad, N., Ochi, A., Heindel, D. W., ... Miller, G. (Accepted/In press). Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance. Nature Medicine. https://doi.org/10.1038/nm.4314

Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance. / Daley, Donnele; Mani, Vishnu R.; Mohan, Navyatha; Akkad, Neha; Ochi, Atsuo; Heindel, Daniel W.; Lee, Ki Buom; Zambirinis, Constantinos P.; Pandian, Gautam SD Balasubramania; Savadkar, Shivraj; Torres-Hernandez, Alejandro; Nayak, Shruti; Wang, Ding; Hundeyin, Mautin; Diskin, Brian; Aykut, Berk; Werba, Gregor; Barilla, Rocky M.; Rodriguez, Robert; Chang, Steven; Gardner, Lawrence; Mahal, Lara; Ueberheide, Beatrix; Miller, George.

In: Nature Medicine, 10.04.2017.

Research output: Contribution to journalArticle

Daley, D, Mani, VR, Mohan, N, Akkad, N, Ochi, A, Heindel, DW, Lee, KB, Zambirinis, CP, Pandian, GSDB, Savadkar, S, Torres-Hernandez, A, Nayak, S, Wang, D, Hundeyin, M, Diskin, B, Aykut, B, Werba, G, Barilla, RM, Rodriguez, R, Chang, S, Gardner, L, Mahal, L, Ueberheide, B & Miller, G 2017, 'Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance', Nature Medicine. https://doi.org/10.1038/nm.4314
Daley, Donnele ; Mani, Vishnu R. ; Mohan, Navyatha ; Akkad, Neha ; Ochi, Atsuo ; Heindel, Daniel W. ; Lee, Ki Buom ; Zambirinis, Constantinos P. ; Pandian, Gautam SD Balasubramania ; Savadkar, Shivraj ; Torres-Hernandez, Alejandro ; Nayak, Shruti ; Wang, Ding ; Hundeyin, Mautin ; Diskin, Brian ; Aykut, Berk ; Werba, Gregor ; Barilla, Rocky M. ; Rodriguez, Robert ; Chang, Steven ; Gardner, Lawrence ; Mahal, Lara ; Ueberheide, Beatrix ; Miller, George. / Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance. In: Nature Medicine. 2017.
@article{2002c324e43040b2ab3923a908f0dbbb,
title = "Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance",
abstract = "The progression of pancreatic oncogenesis requires immune-suppressive inflammation in cooperation with oncogenic mutations. However, the drivers of intratumoral immune tolerance are uncertain. Dectin 1 is an innate immune receptor crucial for anti-fungal immunity, but its role in sterile inflammation and oncogenesis has not been well defined. Furthermore, non-pathogen-derived ligands for dectin 1 have not been characterized. We found that dectin 1 is highly expressed on macrophages in pancreatic ductal adenocarcinoma (PDA). Dectin 1 ligation accelerated the progression of PDA in mice, whereas deletion of Clec7a—the gene encoding dectin 1—or blockade of dectin 1 downstream signaling was protective. We found that dectin 1 can ligate the lectin galectin 9 in mouse and human PDA, which results in tolerogenic macrophage programming and adaptive immune suppression. Upon disruption of the dectin 1–galectin 9 axis, CD4+ and CD8+ T cells, which are dispensable for PDA progression in hosts with an intact signaling axis, become reprogrammed into indispensable mediators of anti-tumor immunity. These data suggest that targeting dectin 1 signaling is an attractive strategy for developing an immunotherapy for PDA.",
author = "Donnele Daley and Mani, {Vishnu R.} and Navyatha Mohan and Neha Akkad and Atsuo Ochi and Heindel, {Daniel W.} and Lee, {Ki Buom} and Zambirinis, {Constantinos P.} and Pandian, {Gautam SD Balasubramania} and Shivraj Savadkar and Alejandro Torres-Hernandez and Shruti Nayak and Ding Wang and Mautin Hundeyin and Brian Diskin and Berk Aykut and Gregor Werba and Barilla, {Rocky M.} and Robert Rodriguez and Steven Chang and Lawrence Gardner and Lara Mahal and Beatrix Ueberheide and George Miller",
year = "2017",
month = "4",
day = "10",
doi = "10.1038/nm.4314",
language = "English (US)",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance

AU - Daley, Donnele

AU - Mani, Vishnu R.

AU - Mohan, Navyatha

AU - Akkad, Neha

AU - Ochi, Atsuo

AU - Heindel, Daniel W.

AU - Lee, Ki Buom

AU - Zambirinis, Constantinos P.

AU - Pandian, Gautam SD Balasubramania

AU - Savadkar, Shivraj

AU - Torres-Hernandez, Alejandro

AU - Nayak, Shruti

AU - Wang, Ding

AU - Hundeyin, Mautin

AU - Diskin, Brian

AU - Aykut, Berk

AU - Werba, Gregor

AU - Barilla, Rocky M.

AU - Rodriguez, Robert

AU - Chang, Steven

AU - Gardner, Lawrence

AU - Mahal, Lara

AU - Ueberheide, Beatrix

AU - Miller, George

PY - 2017/4/10

Y1 - 2017/4/10

N2 - The progression of pancreatic oncogenesis requires immune-suppressive inflammation in cooperation with oncogenic mutations. However, the drivers of intratumoral immune tolerance are uncertain. Dectin 1 is an innate immune receptor crucial for anti-fungal immunity, but its role in sterile inflammation and oncogenesis has not been well defined. Furthermore, non-pathogen-derived ligands for dectin 1 have not been characterized. We found that dectin 1 is highly expressed on macrophages in pancreatic ductal adenocarcinoma (PDA). Dectin 1 ligation accelerated the progression of PDA in mice, whereas deletion of Clec7a—the gene encoding dectin 1—or blockade of dectin 1 downstream signaling was protective. We found that dectin 1 can ligate the lectin galectin 9 in mouse and human PDA, which results in tolerogenic macrophage programming and adaptive immune suppression. Upon disruption of the dectin 1–galectin 9 axis, CD4+ and CD8+ T cells, which are dispensable for PDA progression in hosts with an intact signaling axis, become reprogrammed into indispensable mediators of anti-tumor immunity. These data suggest that targeting dectin 1 signaling is an attractive strategy for developing an immunotherapy for PDA.

AB - The progression of pancreatic oncogenesis requires immune-suppressive inflammation in cooperation with oncogenic mutations. However, the drivers of intratumoral immune tolerance are uncertain. Dectin 1 is an innate immune receptor crucial for anti-fungal immunity, but its role in sterile inflammation and oncogenesis has not been well defined. Furthermore, non-pathogen-derived ligands for dectin 1 have not been characterized. We found that dectin 1 is highly expressed on macrophages in pancreatic ductal adenocarcinoma (PDA). Dectin 1 ligation accelerated the progression of PDA in mice, whereas deletion of Clec7a—the gene encoding dectin 1—or blockade of dectin 1 downstream signaling was protective. We found that dectin 1 can ligate the lectin galectin 9 in mouse and human PDA, which results in tolerogenic macrophage programming and adaptive immune suppression. Upon disruption of the dectin 1–galectin 9 axis, CD4+ and CD8+ T cells, which are dispensable for PDA progression in hosts with an intact signaling axis, become reprogrammed into indispensable mediators of anti-tumor immunity. These data suggest that targeting dectin 1 signaling is an attractive strategy for developing an immunotherapy for PDA.

UR - http://www.scopus.com/inward/record.url?scp=85017279150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017279150&partnerID=8YFLogxK

U2 - 10.1038/nm.4314

DO - 10.1038/nm.4314

M3 - Article

C2 - 28394331

AN - SCOPUS:85017279150

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

ER -